Can supersaturation save us from solubility problems?

Bioterrorism concerns prompt the UK government to fund development of a vaccine for plague.

Genentech’s Cell Culture Biologics Drug Substance Plant 2 in Vacaville, California.

The EMA says “yes” to transparency, but some pharma companies have other ideas.

A consortium of vendors and pharma companies search for a single, serialization standard.

Are reduced GDUFA fees on the horizon for contract manufacturers?

Lyophilized gene networks synthesize biomedicines ondemand – with just a sprinkle of water.

Why has Médecins Sans Frontières rejected an offer of free vaccines from Pfizer?

This article explains how an inline probe was used to monitor a granulation at three different scales to confirm that, in each case, the granules produced were the same size, and more importantly produced tablets of identical quality as quantified by hardness.

Experts come together to discuss the chemistry of solubility and the drug delivery solutions of the future for dealing with poorly soluble compounds.